Clinical Trials Logo
  1. Home
  2. Lung Neoplasms
  3. NCT03081741
  4. Details
NCT03081741 Clinical Trial

Circulating Tumor DNA in Surgical Lung Cancer Patients

Lung Neoplasms Clinical Trial

Official title:
A Prospective Study of Circulating Tumor DNA Detection in Surveillance for Lung Cancer Patients

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03081741
Other study ID # GeneHealth-LC-01
Secondary ID
Status Recruiting
Phase N/A
First received March 12, 2017
Last updated May 22, 2017
Start date May 3, 2017
Est. completion date March 18, 2020

Study information
Verified date May 2017
Source Shenzhen Gene Health Bio Tech Co., Ltd.
Contact Chaoyu Liu, PhD
Phone +8675588858978-808
Email lcy@genehe.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Conduct a prospective study to detect the change of ctDNA of surgical lung cancer patients.

Description:

Studies have shown the feasibility of detecting mutation status by blood circulating tumor DNA (ctDNA) in lung cancer patients.

The investigators plan to test the blood ctDNA in surveillance of surgical lung cancer patients. And evaluate the correlation between ctDNA level with tumor relapse or metastasis.

Recruitment information / eligibility
Status Recruiting
Enrollment 500
Est. completion date March 18, 2020
Est. primary completion date December 1, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

Aged 18 to 80 years Undergo radical surgery Histologically confirmed diagnosis of lung cancer Considered primary lung cancer by clinical criteria Patients must have given written informed consent

Exclusion Criteria:

Unable to comply with the study procedure Malignant tumor history Patients who received any treatment prior to resection Unqualified blood samples

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
China Shenzhen Second People's Hospital Shenzhen Guangdong

Sponsors (4)
Lead Sponsor Collaborator
Shenzhen Gene Health Bio Tech Co., Ltd. Peking University Shenzhen Hospital, Shenzhen People's Hospital, Shenzhen Second People's Hospital

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Effect of surgery on ctDNA of lung cancer patients Changes of blood ctDNA of lung cancer patients before and after surgery. before surgery and 7days after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT03357094 - Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function N/A
Recruiting NCT05543954 - 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients Early Phase 1
Completed NCT01114958 - Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases Phase 1
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Not yet recruiting NCT02907606 - Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study N/A
Completed NCT02926768 - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Phase 1
Active, not recruiting NCT02514512 - Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking N/A
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Completed NCT02531737 - Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer Phase 2
Active, not recruiting NCT02284633 - Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
Completed NCT02106143 - RejuvenAir™ System Lobectomy Safety and Histology Study N/A
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Enrolling by invitation NCT01687647 - Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure Phase 3
Completed NCT00351962 - Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours N/A
Completed NCT00243685 - Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Phase 2/Phase 3
Terminated NCT00356525 - Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor Phase 2
Completed NCT00385177 - Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors Phase 1
Completed NCT00129844 - Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer Phase 2
Withdrawn NCT00090701 - A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer Phase 2
Recruiting NCT01789229 - Establishment of a Tumor Bank for Tissue Samples